RBC Capital Downgrades Pacira BioSciences to Sector Perform, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has downgraded Pacira BioSciences (NASDAQ:PCRX) from Outperform to Sector Perform and lowered the price target from $37 to $14.
August 12, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has downgraded Pacira BioSciences from Outperform to Sector Perform and significantly lowered the price target from $37 to $14.
The downgrade from Outperform to Sector Perform and the substantial reduction in the price target from $37 to $14 by RBC Capital is likely to negatively impact investor sentiment and the stock price of Pacira BioSciences in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100